Bharat Biotech releases Phase 3 results of Covaxin, says it shows 81% interim clinical efficacy
3 years, 9 months ago

Bharat Biotech releases Phase 3 results of Covaxin, says it shows 81% interim clinical efficacy

India Today  

Indian vaccine manufacturer Bharat Biotech on Wednesday announced results of Phase 3 clinical trials of its Covid-19 vaccine candidate, Covaxin, saying the vaccine demonstrates interim clinical efficacy of 81 per cent. Bharat Biotech said the Phase 3 clinical trials for Covaxin involved 25,800 volunteers, making it the "largest trials ever conducted in India" in collaboration with the Indian Council of Medical Research. "Covaxin has demonstrated 81 per cent interim efficacy in preventing Covid-19 in those without prior infection after the second dose," Bharat Biotech said. "With today's results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech said.

India Results Phase Bharat Vaccine Interim Clinical Phase 3 Bharat Biotech Biotech Covaxin  phase  vaccine  results  shows  cases  efficacy  covaxin  releases  trials  bharat  clinical  covid19  interim  biotech

History of this topic

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
4 months, 3 weeks ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister
4 months, 3 weeks ago

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister

New Indian Express  

NEW DELHI: Union health minister J P Nadda on Friday said that Bharat Biotech initially did not mention ICMR and NIV as co-inventors in the patent application for Covaxin and the application was corrected after objections were raised by the government. Covaxin, which was widely used as a Covid vaccine, was jointly developed by the Indian Council of Medical Research, …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR
6 months ago

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR

The Hindu  

India’s first indigenously developed coronavirus vaccine, Covaxin, was a joint collaboration between the Indian Council of Medical Research and the Hyderabad-based Bharat Biotech International Limited with intellectual property rights jointly shared between the two organisations. The Minister’s statement said the ICMR would provide a “well characterised” virus strain for vaccine development, the BBIL would develop the final vaccine formulation and, …

BHU’s Covaxin safety study riddled with major limitations
6 months, 4 weeks ago

BHU’s Covaxin safety study riddled with major limitations

The Hindu  

An observational study carried out by researchers from the Banaras Hindu University, Varanasi to assess the safety of Covaxin, particularly the long-term adverse events of special interest one year after vaccination, in adolescents and adults has been criticised by ICMR for the poor study design. Given the limitations of the study one can “certainly say that the study can’t be …

BHU study on Covaxin side effects poorly designed, erroneously acknowledges ICMR: Dr Bahl
7 months ago

BHU study on Covaxin side effects poorly designed, erroneously acknowledges ICMR: Dr Bahl

Deccan Chronicle  

New Delhi: The Indian Council of Medical Research Director General Dr Rajiv Bahl on Monday criticised a recently published study on the long-term safety analysis of the Covaxin in adults and adolescents for its poor methodology and design, and clarified the article misleadingly and erroneously "acknowledges" ICMR. A research paper, titled 'Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in …

1 in 3 Covaxin takers reported adverse events, BHU study claims
7 months, 1 week ago

1 in 3 Covaxin takers reported adverse events, BHU study claims

Hindustan Times  

A one-year follow-up study conducted by researchers at Banaras Hindu University has found that nearly one-third of individuals who received Bharat Biotech's Covaxin reported 'adverse events of special interest'. Read: AstraZeneca Covid vaccine related to another rare but deadly blood clotting disorder Adverse Events of Special Interest: Around 33% of participants reported AESI, with new-onset skin and subcutaneous disorders, general …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021
7 months, 2 weeks ago

After AstraZeneca covid-19 vax recall worldwide, Serum says it stopped manufacturing jabs in Dec 2021

Live Mint  

New Delhi: The Serum Institute of India on Wednesday said it has stopped making and supplying covid-19 vaccine Covishield after AstraZeneca, the British drugmaker that helped develop the vaccine, announced it too was withdrawing its version of the jab worldwide. The development follows the launch of a class action suit in the UK over allegations that the UK vaccine caused …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Covishield more effective than Covaxin: Study
9 months, 2 weeks ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
9 months, 2 weeks ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 5 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs
1 year, 6 months ago

India’s Winning Formula: Making Healthcare Affordable and Accessible with PPPs

News 18  

In the last 75 years, India’s progress as a nation has been both inspiring and impressive. Vaccine PPPs during the Covid-19 pandemic It is during the pandemic that India gained a definite advantage in the global health space, when it administered the first dose of the indigenous Covid-19 vaccine Covaxin, in January 2021. Within a year of the emergence of …

Serum Institute of India to produce 5mn Covishield doses in two months
1 year, 8 months ago

Serum Institute of India to produce 5mn Covishield doses in two months

Hindustan Times  

Serum Institute of India chief executive officer Adar Poonawalla, while underlining that the current strain of Covid is mild and the demand for vaccine shots is low, said his firm will produce five to six million Covishield doses in the next two to three months and same amount of stock is already available for Covovax. According to Poonawalla, SII has …

India restarts Covid vaccine production as new infections soar 30% in one day
1 year, 8 months ago

India restarts Covid vaccine production as new infections soar 30% in one day

The Independent  

India is ramping up its vaccine production following a rapid surge in Covid-19 cases driven by a new subvariant dubbed Arcturus. The country recorded 10,158 news Covid cases on Thursday, a 30 per cent surge in one day, according to the federal health ministry data. The company stopped manufacturing Covishield in December 2021 due to dwindling demand and a low …

Studies show XBB.1.16 is not clinically more severe
1 year, 8 months ago

Studies show XBB.1.16 is not clinically more severe

Hindustan Times  

The XBB.1.16 sub-variant of the Omicron strain of the SARS-CoV-2 virus that causes Covid does not exhibit higher clinical severity according to preliminary results from laboratory studies being conducted in the country to know disease characteristics, according to people familiar with the matter. According to the World Health Organisation, mutations at position 478 of the SARS-CoV-2 spike protein have been …

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India
1 year, 10 months ago

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India

Live Mint  

The world's first intranasal heterologous booster dose has begun to be dispatched by Bharat Biotech to hospitals, Executive Chairman Dr. Krishna Ella announced on February 5. He discussed the delivery of vaccines under the bilateral agreement between the Ella Foundation and the UW-Madison Global Health Institute for the establishment of the first-ever UW-Madison One Health Center in India for improving …

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella
1 year, 10 months ago

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

India TV News  

COVID-19 vaccine : Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. "We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said. Establishing the UW-Madison Global One Health Centre holds great significance as …

India launches world’s 1st intranasal Covid vaccine: Check price, availability
1 year, 10 months ago

India launches world’s 1st intranasal Covid vaccine: Check price, availability

Hindustan Times  

The world's first made-in-India intranasal Covid-19 vaccine iNCOVACC, manufactured by Bharat Biotech, was launched on Thursday as the country marked its 74th Republic Day. Union health minister Mansukh Mandaviya launched the vaccine and emphasised India's vaccine manufacturing and innovation capability, which he said is appreciated all over the world. "As the world's first intranasal Covid-19 vaccine, this is a glorious …

What is nasal vaccine - iNCOVACC? All you need to know
1 year, 10 months ago

What is nasal vaccine - iNCOVACC? All you need to know

India TV News  

Covid19 nasal vaccine : Union Health Minister Mansukh Mandaviya on Friday launched Bharat Biotech's first India-made nasal Vaccine, iNCOVACC, as a booster shot for Covid19. According to Bharat Biotech, the nasal vaccine is likely to prevent infection, thus, preventing the transmission of the virus. The event saw the Union Minister of State Science & Technology; Minister of State Earth Sciences; …

Centre rolls out first nasal Covid vaccine as booster
1 year, 10 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 10 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

India’s first intra-nasal Covid-19 vaccine iNCOVACC launched
1 year, 10 months ago

India’s first intra-nasal Covid-19 vaccine iNCOVACC launched

Live Mint  

Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched India's first made nasal vaccine against Covid-19 iNCOVACC. "Our nasal vaccine will be officially launched on January 26, on Republic Day," the company's chairman and managing director Krishna Ella said, participating in the 'Face-to-Face with New Frontiers in Science' segment of the IISF, organised at the …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

COVID-19: Health Minister Mansukh Mandaviya to launch world's 1st 'Made-in-India' nasal vaccine today
1 year, 10 months ago

COVID-19: Health Minister Mansukh Mandaviya to launch world's 1st 'Made-in-India' nasal vaccine today

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya will launch 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday, official sources said. According to the sources, Hyderabad-based Bharat Biotech's Intranasal heterologous booster dose is likely to be available in the market by February first week.Recently, Bharat Biotech announced iNCOVACC® as a booster dose in the country.Earlier this …

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26
1 year, 11 months ago

Bharat Biotech’s nasal vaccine likely to be launched on Jan 26

Hindustan Times  

Bhopal: Bharat Biotech’s nasal Covid-19 vaccine iNCOVACC is expected to be launched on January 26, executive chairman Krishna Ella said at an event on Saturday. “Our nasal vaccine will be officially launched on January 26 on Republic Day,” Ella told students at the Maulana Azad National Institute of Technology in Bhopal, where the India International Science Festival, 2022, is being …

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26
1 year, 11 months ago

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26

India TV News  

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella said here on Saturday. In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey
1 year, 11 months ago

Time to Join this ‘Herd’: 39% Have Boosted Their Protection against Covid Virus, Finds Survey

News 18  

At least 39% of respondents have already taken the Covid vaccine booster dose, while 6% plan to take the injectable booster and 4% the nasal one, a LocalCircles survey has found. Amid the uptick in Covid in cases in China and other countries, the Centre gave nod for Bharat Biotech’s intranasal COVID vaccine iNCOVAAC as a booster dose. Director General …

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla
1 year, 11 months ago

COVID-19: Covovax vaccine to get approval as booster dose in 10-15 days, says Poonawalla

Firstpost  

Pune: Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Poonawalla told the media that the vaccine works very well against the Omicron variant of coronavirus. Speaking to reporters on the sidelines of an event at the Bharati …

Covovax vaccine will get approval in next 10-15 days, says SII CEO Poonawalla
1 year, 11 months ago

Covovax vaccine will get approval in next 10-15 days, says SII CEO Poonawalla

Hindustan Times  

Chief Executive Officer of Serum Institute of India, Adar Poonawalla, has said their Covovax vaccine will get approval as a booster dose against Covid-19 in the next 10 to 15 days. Adar Poonawalla, chief executive officer of Serum Institute of India Speaking to reporters on the sidelines of an event at the Bharati Vidyapeeth University here on Sunday, the SII …

Covovax to get approval as booster in 10-15 days, says SII’s Adar Poonawalla
1 year, 11 months ago

Covovax to get approval as booster in 10-15 days, says SII’s Adar Poonawalla

Live Mint  

As India braces for a possible rise in COVID-19 cases, a new vaccine is set to join the ranks as booster this month. Serum Institute of India's Covovax vaccine - which is effective against the Omicron strains - will get approval as a booster jab against COVID-19 in the next 10 to 15 days. All you need to know about …

No second Covid-19 booster dose required: Report
1 year, 11 months ago

No second Covid-19 booster dose required: Report

Live Mint  

There is no need to take a second booster dose against Covid-19 infection, news agency ANI reported on Tuesday citing government sources. According to the data by the Union Health Ministry, a total of 220.11 crore vaccine doses have been administered in the country, of which 95.13 crore have taken the second dose while only 22.41 crore of the population …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
1 year, 11 months ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Bharat Biotech’s intranasal covid vaccine priced at ₹325 for govt hospitals
1 year, 11 months ago

Bharat Biotech’s intranasal covid vaccine priced at ₹325 for govt hospitals

Live Mint  

NEW DELHI: Bharat Biotech’s intranasal covid-19 vaccine--iNCOVACC --will be available for ₹325 per dose at government hospitals, and for ₹800 in private settings, the pharma major said on Tuesday. According to the company, iNCOVACC is the world’s first intranasal vaccine for covid-19 to have received approval for a primary two-dose schedule, and as a heterologous booster dose. Clinical trials were …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
1 year, 11 months ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here
1 year, 11 months ago

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above according to reports will be available at ₹800+ GST+ hospital charges according to sources. The country’s first intranasal covid vaccine will be rolled out in the fourth week of January as a booster dose for those …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

Bharat Biotech’s nasal vaccine on CoWIN app today: All you need to know
2 years ago

Bharat Biotech’s nasal vaccine on CoWIN app today: All you need to know

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above and is likely to be introduced on the Co-WIN platform Friday evening. What is the new nasal vaccine developed by Bharat Biotech? This vaccine candidate was evaluated in phase I, II and III clinical trials with …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use
2 years ago

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use

Live Mint  

World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation for restricted use in emergency situations in the age group of 18 and above. A press release from the vaccine maker said iNCOVACC, a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein, is the world's first …

Discover Related